Literature DB >> 16446476

On bias and transparency in the development of influential recommendations.

Andreas Laupacis1.   

Abstract

Mesh：

Year:  2006        PMID： 16446476      PMCID： PMC1373717          DOI： 10.1503/cmaj.051622

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.

Authors:  An-Wen Chan; Asbjørn Hróbjartsson; Mette T Haahr; Peter C Gøtzsche; Douglas G Altman
Journal:  JAMA       Date:  2004-05-26       Impact factor: 56.272

2.  Conflicts of interest and independent data analysis in industry-funded studies.

Authors:  Caroline J Loew
Journal:  JAMA       Date:  2005-11-23       Impact factor: 56.272

3.  Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors.

Authors:  Catherine D De Angelis; Jeffrey M Drazen; Frank A Frizelle; Charlotte Haug; John Hoey; Richard Horton; Sheldon Kotzin; Christine Laine; Ana Marusić; A John P M Overbeke; Torben V Schroeder; Hal C Sox; Martin B Van Der Weyden
Journal:  CMAJ       Date:  2005-05-23       Impact factor: 8.262

Review 4.  Challenges in systematic reviews that assess treatment harms.

Authors:  Roger Chou; Mark Helfand
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

5.  Publication bias in clinical research.

Authors:  P J Easterbrook; J A Berlin; R Gopalan; D R Matthews
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321
  5 in total
  8 in total

1.  Evidence and advocacy: are all things considered?

Authors:  Jeffrey A Johnson; Alun L Edwards
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

Review 2.  Moving from opacity to transparency in pharmaceutical policy.

Authors:  Irfan Dhalla; Andreas Laupacis
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

3.  Transparency in reimbursement decisions: in whose best interest?

Authors:  Tania Stafinski; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

4.  Potential Conflict of Interest and Bias in the RACGP's Smoking Cessation Guidelines: Are GPs Provided with the Best Advice on Smoking Cessation for their Patients?

Authors:  Ross MacKenzie; Wendy Rogers
Journal:  Public Health Ethics       Date:  2015-04-20       Impact factor: 1.940

Review 5.  Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review.

Authors:  Sahar Tabatabavakili; Rishad Khan; Michael A Scaffidi; Nikko Gimpaya; David Lightfoot; Samir C Grover
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-01-19

Review 6.  Conflict of interest in clinical practice guideline development: a systematic review.

Authors:  Susan L Norris; Haley K Holmer; Lauren A Ogden; Brittany U Burda
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

7.  Guideline standardisation, cost effectiveness, industry needs and conflict of interest.

Authors: 
Journal:  Mens Sana Monogr       Date:  2007-01

8.  Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease.

Authors:  Karam Elsolh; Daniel Tham; Michael A Scaffidi; Nikko Gimpaya; Rishi Bansal; Nazi Torabi; Juana Li; Yash Verma; Rishad Khan; Samir C Grover
Journal:  J Can Assoc Gastroenterol       Date:  2022-06-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.